According to Zacks, “Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company’s lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative breast cancer which is in clinical stage. It operates principally in New York and San Diego. Zentalis Pharmaceuticals, Inc. is based in NEW YORK. “
Other analysts have also issued reports about the stock. Stifel Nicolaus reduced their price target on shares of Zentalis Pharmaceuticals from $94.00 to $74.00 in a research note on Monday, April 11th. Oppenheimer reduced their price target on shares of Zentalis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating for the company in a research note on Tuesday, April 12th. SVB Leerink reduced their price target on shares of Zentalis Pharmaceuticals from $78.00 to $67.00 and set an “outperform” rating for the company in a research note on Tuesday, April 12th. Wells Fargo & Company started coverage on shares of Zentalis Pharmaceuticals in a research note on Wednesday, April 6th. They issued an “overweight” rating and a $67.00 price target for the company. Finally, Wedbush reissued an “outperform” rating on shares of Zentalis Pharmaceuticals in a research note on Friday, February 25th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $76.33.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last issued its quarterly earnings results on Thursday, February 24th. The company reported ($1.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.23. During the same quarter last year, the business earned ($1.01) earnings per share. On average, equities analysts predict that Zentalis Pharmaceuticals will post -5.03 EPS for the current year.
In other news, CFO Melissa B. Epperly sold 17,080 shares of the business’s stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $50.09, for a total transaction of $855,537.20. Following the sale, the chief financial officer now owns 247,414 shares in the company, valued at $12,392,967.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Melissa B. Epperly sold 1,913 shares of the company’s stock in a transaction that occurred on Wednesday, February 23rd. The shares were sold at an average price of $49.10, for a total transaction of $93,928.30. The disclosure for this sale can be found here. Insiders have sold 153,307 shares of company stock worth $7,527,251 in the last 90 days. 21.00% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC acquired a new position in Zentalis Pharmaceuticals in the 4th quarter valued at approximately $47,000. Fieldpoint Private Securities LLC acquired a new position in shares of Zentalis Pharmaceuticals during the 4th quarter worth $76,000. Dark Forest Capital Management LP acquired a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth $79,000. IFP Advisors Inc bought a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth $102,000. Finally, Advisor Group Holdings Inc. boosted its holdings in shares of Zentalis Pharmaceuticals by 1,082.5% during the 4th quarter. Advisor Group Holdings Inc. now owns 1,218 shares of the company’s stock worth $102,000 after buying an additional 1,115 shares during the period. Hedge funds and other institutional investors own 94.61% of the company’s stock.
About Zentalis Pharmaceuticals (Get Rating)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
- What Should Investors Take Away From Boston Beer’s Earnings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.